PT - JOURNAL ARTICLE AU - Cecelia J. Madison AU - Ryan A. Melson AU - Michael J. Conlin AU - Kenneth R. Gundle AU - Reid F. Thompson AU - David C. Calverley TI - Thromboembolic risk in lung cancer patients receiving systemic therapy AID - 10.1101/2020.12.21.20248675 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.21.20248675 4099 - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248675.short 4100 - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248675.full AB - In this retrospective study, we investigated the influence of chemotherapy and immunotherapy on thromboembolic risk among US Veterans with lung cancer during their first six months of systemic therapy. Patients in the study cohort received treatment with common frontline agents that were divided into four groups: chemotherapy alone, immunotherapy alone, combination of chemo- and immunotherapies, and molecularly targeted therapies. The latter served as a control group of systemically treated lung cancer patients who received neither chemotherapy nor immunotherapy. The cohort experienced a 6.8% overall incidence of thromboembolic events with a median time to event of 49 days, but the analysis demonstrated significantly different rates among the different treatment groups. We explored models incorporating multiple confounding variables as well as the competing risk of death, and these results indicated that both chemotherapy and immunotherapy were associated with an increased incidence of thrombosis, either when given alone or combined, compared with the control group (6.91%, 9.09%, and 7.47% respectively versus 3.68%, p < 0.024). Both the Khorana score assessing thrombosis risk for cancer patients and the Charlson comorbidity score were found to be associated with increased risk of thrombosis in our analyses. Paradoxically, we found an association between risk of thrombosis and the use of prophylactic anticoagulation or aspirin during the first month of systemic treatment, accounting for several confounding variables including a patient’s prior history of thrombosis. Additionally, our data suggest that thromboembolic events may occur more commonly in lung cancer patients treated with immunotherapy compared with chemotherapy. Further study is warranted to better determine the drivers of thromboembolic risk and to identify ways to mitigate this risk for patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by VA Career Development Award (1 IK2 CX002049-01) to RFT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Portland VA IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPatient-level data is available only to qualified VA researchers.